UBS Raises its Price Target on MetLife (MET) to $102

MetLife, Inc. (NYSE:MET) is one of the 8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, UBS raised the price target on MetLife, Inc. (NYSE:MET) to $102 from $98 and maintained a Buy rating. UBS said the update reflects changes across the North American life insurance group ahead of Q1 earnings, noting continued focus on disability margins with “relatively limited wiggle-room” given cyclicality and economic uncertainty, while rolling its valuation to 2027 estimates.

On the same day, MetLife Investment Management said it originated approximately $26B in private fixed income transactions in 2025, bringing total assets under management on its platform to $144.7B as of December 31, 2025. The platform includes private corporate and infrastructure debt, asset-based finance, residential loans, and sustainable finance, with originations including $8.9B in residential credit, $6.8B in corporate debt, $5.7B in infrastructure debt, and $4.5B in asset-based finance.

UBS Raises its Price Target on MetLife (MET) to $102

On April 8, 2026, Barclays lowered its price target on MetLife to $89 from $92 and maintained an Overweight rating. Barclays said premium growth and broker organic growth are expected to remain sluggish, but noted that margins and capital deployment should continue to support book value growth.

MetLife, Inc. (NYSE:MET) provides insurance, asset management, and financial services globally.

While we acknowledge the risk and potential of MET as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MET and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.